Sivopixant + Placebo + Acetazolamide + SASS-001
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Apnea
Conditions
Sleep Apnea
Trial Timeline
Apr 2, 2025 → Dec 1, 2025
NCT ID
NCT06776432About Sivopixant + Placebo + Acetazolamide + SASS-001
Sivopixant + Placebo + Acetazolamide + SASS-001 is a phase 2 stage product being developed by Shionogi for Sleep Apnea. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06776432. Target conditions include Sleep Apnea.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06776432 | Phase 2 | Recruiting |
Competing Products
20 competing products in Sleep Apnea